



10/06/06 6235-59221-01 593085 MED-A0102P-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Morishita et al.

Application No. 09/869,475
Filed: October 10, 2001
Confirmation No. 4309
For: GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE
Examiner: Brian A. Whiteman
Art Unit: 1635
Attorney Reference No. 6235-59221-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP RCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below

Attorney or Agent for Applicant(s) [Signature]
Date Mailed October 6, 2006

MAIL STOP RCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(4)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By [Signature]
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing

 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>	Attorney Docket Number	6235-59221-01
	Application Number	09/869,475
	Filing Date	October 10, 2001
	First Named Inventor	Morishita
	Art Unit	1635
	Examiner Name	Brian A. Whiteman

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Denham et al., "Cationic Liposome-Medicated Gene Transfer During Acute Pancreatitis: Tissue Specificity, Duration, and Effects of Acute Inflammation," <i>J. Gastrointest. Surg.</i> 2:95-101 (1998).
		Denham et al., "Transient Human Gene Therapy, a Novel Cytokine Regulatory Strategy for Experimental Pancreatitis," <i>Ann. Surg.</i> 227:812-820 (1998).
		Kurata et al., "Recombinant Adenovirus Vectors for Cytokine Gene Therapy in Mice," <i>J. Allergy Clin. Immunol.</i> 103:S471-S484 (1999).
		Thornton et al., "Enhanced Collagen Accumulation Following Direct Transfection of the Inducible Nitric Oxide Synthase Gene in Cutaneous Wounds," <i>Biochem. Biophys. Res. Comm.</i> 246:654-659 (1998).
		Vogel, "A Direct In Vivo Approach for Skin Gene Therapy," <i>Proc. Assoc. Am. Physicians</i> 111:190-197 (1999).

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.